Using EU-ME3 Endoscopic Ultrasound to Measure Liver Fibrosis in Adults With Chronic Liver Disease Comparing EUS-SWQ and FibroScan Results with Liver Biopsy Findings

What this Trial Is About

Researchers are evaluating the use of the Olympus EU-ME3 endoscopic ultrasound shear wave quantification EUS-SWQ function to diagnose and grade liver fibrosis in adults with chronic liver disease. The study aims to determine how closely EUS-SWQ measurements match liver fibrosis stages identified by liver biopsy, which is the standard method. It also compares EUS-SWQ results with FibroScan measurements and assesses the safety and success rate of EUS-SWQ in this setting. This is a prospective, single-center observational study involving 65 adult patients scheduled for clinically indicated liver biopsy. Participants will undergo EUS-SWQ and FibroScan examinations before the biopsy. These procedures are standard clinical tests, and no experimental drugs or devices are used. The study will monitor participants for any discomfort or adverse events related to the procedures. Participants will be assessed for liver fibrosis using liver biopsy pathology and EUS-SWQ measurements, with comparisons to FibroScan results. The primary outcome is the correlation between EUS-SWQ and liver fibrosis staging based on biopsy, evaluated two weeks after the intervention. Secondary outcomes include comparing the correlation of EUS-SWQ and FibroScan with liver fibrosis and the safety and measurement success rate of EUS-SWQ at baseline. The total participation duration covers the time needed for these examinations and follow-up assessments.

Correlation Of EUS-SWQ And Liver Fibrosis Pathology In Chronic Liver Disease